Follow us on LinkedIn


A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care

Ethical Approval Granted for I-SCREEN's WP4 Community-Based Screening Study

The I-SCREEN consortium is pleased to announce that the I-SCREEN clinical study has obtained ethical approval for WP4 of the PYRENEES study in Vienna. This is a major milestone that enables us to kick off this innovative, first-of-its kind project.

Highlights of the WP4 Study:

  • Screening Locations: Participants will be screened at optician and optometrist centers in six countries: UK, Austria, Slovenia, Switzerland, France, and Spain.
  • Patient-Centric Approach: All collected OCT scans will be evaluated at the Medical University of Vienna by telemedicine doctors to ensure patient safety.
  • Seamless Referral Process: Participants diagnosed with AMD will be referred to paired clinical sites, where they may join the WP1 study (SUDETES/APENNINES) for further treatment and research.

We are proud to be advancing the field of ophthalmology and improving patient outcomes through innovative screening and treatment methods.

Stay tuned for more updates as we move forward with this innovative approach to community-based screening for AMD patients!